Neuroblastomas generally arise from the adrenal medulla and the sympathetic nervous chain. Approximately 65% of the tumours are located in the abdomen and 35% in other sites, often the sympathetic chain in the thorax'. The tumours have been described in several unusual sites including the blad-der2, sciatic nerve3, jaw, neck and nasopharynx4. Neuroblastomas ofthe small intestine have only been reported twice before. Ritter in 19255 described two cases in adults aged 55 and 64. One of these patients had a very large tumour incorporating the upper part of the mesentery and several loops of jejeunum and only apparently arose from the bowel wall. In the second patient described, the histology of the small bowel tumour was relatively benign; the author commented on the atypical appearance and a diagnosis of neuroblastoma was not definitely established.
We believe that the tumour in our patient arose primarily from the autonomic nerve cells in the myenteric plexus of Auerbach. However, it is conceivable that this was an isolated metastasis from a primary tumour which had undergone spontaneous regression. This phenomenon is largely confined to children under the age of 2 years6. Some tumours regress as a result of necrosis and others are thought to mature to become ganglioneuromas over a period of years. Willis7 thought that this was more likely to occur in girls. Gastrointestinal ganglioneuromas have been well described. Dahl et al.' reviewed 11 cases; ofthese 2 were situated in the terminal ileum, 2 in the stomach, one in the duodenum, 5 in the appendix and 2 involved the colon. The frequency of regression and maturation is variously estimated to be 1-8%'. The maturation of an extra-adrenal neuroblastoma was described by Haber and Bennington'.
We also considered the possibility that this woman's tumour was a metastatic lesion from a fetal primary tumour. However, there was no evidence of neuroblastoma in the infant, nor in the placenta. The normal hydroxymandelic acid levels and the return of the blood pressure to normal after the caesarean section, despite incomplete removal of the tumour, indicate that the lesion was not functionally active.
Friedreich's ataxia is a hereditary disease characterized by degeneration ofthe spinocerebellar tracts, posterior columns and the pyramidal tracts. There has been no previous reported association with neuroblastoma, although patients with this hereditary ataxia do have an increased incidence ofvisceral carcinoma in later life.
Miller'0 failed to show an increased incidence of congenital and hereditary problems in patients with neuroblastoma. However, Chatten and Voorhess " reported a family in which 4 The Royal Society of Medicine Case report A 28-year-old Chinese shop assistant developed severe nausea and vomiting complicating pregnancy. This pregnancy, her first after two years ofmarriage, was clomiphene-induced. On admission she was dehydrated, ketonuric and hypokalaemic. Ultrasound scanning confirmed a singleton pregnancy at a maturity of 12 weeks. Her symptoms initially improved following antiemetic therapy and intravenous fluid replacement.
Subsequently, she required repeated admissions with relapsing hyperemesis (Table 1) . On the third admission, a persisting tachycardia of 120/minute was noted despite rehydration. Her body weight fell from 54.6 kg before pregnancy to 49.7 kg. She had a small goitre and serum thyroxine was elevated at 356 nmol/l. No overt signs of thyrotoxicosis were found at this stage. On the fourth admission, her serum thyroxine had fallen to 177 nmol/l. Her serum calcium was normal. On the sixth admission, the vomiting was so severe that she required parenteral nutritional support with Intralipid, Vamin G and vitamin B complex. Parenteral nutrition was again required on her next two admissions.
On the eighth admission she had a tachycardia of up to 140/minute, a sleeping pulse of 80-90/minute and lid lag. The thyroid gland was diffusely enlarged, a bruit was detected and an adenomatous nodule was found in the right lower lobe by ultrasound scanning. Thyroid function tests showed markedly elevated values with a serum total thyroxine (T4) of484 nmol/l and tri-iodothyronine (T3) 9.0 nmol/l (Figure 1 ). The free T4 and free T3 were 52.5 pmol/l and 29.0 pmol/l respectively. However, the red blood cell zinc level was normal. The thyroxine-binding-globulin (TBG) level was 29.1 mg/l and human chorionic gonadotrophin (HCG) level was 112 000 ul/l. There was no increase in the level of thyroid-stimulating hormone (TSH) in response to injection of thyrotrophinreleasing hormone (TRH). In view of these findings, carbimazole 15mg/day was started at 284 weeks, with marked symptomatic improvement. During this admission up to the day of starting carbimazole, she gained 3.6 kg. When she went home four days later, she gained a further 1.3 kg without nutritional support.
Subsequently at follow up, she admitted that she had stopped taking carbimazole after two weeks because she felt better. As there was satisfactory weight gain, carbimazole was not recommenced. At 34 weeks she went into spontaneous labour and delivered a healthy daughter weighing 2.7 kg. The assessed maturity was 35 weeks and there were no neonatal complications. The postnatal course was uneventful and both the postpartum thyroid function tests and the thyroid size have returned to normal.
Discussion
Nausea and vomiting are common symptoms of uncomplicated early pregnancy. Occasionally, however, an underlying cause may be found. Metabolic disorders, for example hyperthyroidism2"3, can present as hyperemesis gravidarum. Ifthe underlying disorder is unrecognized, thyrotoxic crisis can occur2'5 with very serious consequences, whereas prompt treatment with antithyroid drugs is highly effective.
Unlike many patients with hyperemesis who improve with advancing gestation, our patient had persistent symptoms and weight loss with increasing severity towards the end ofthe second trimester. Her serum T4 and T3 fluctuated but changed in parallel to the severity of her symptoms (Figure 1 ). Both her total and free T4 and T3 levels were greatly elevated suggesting hyperthyroidism. In addition, the TSH response to TRH was absent, as reported for thyrotoxicosis in pregnancy3. This was unlike the situation in hyperemetic and normal pregnant women6. Antithyroid therapy was therefore commenced at 28 weeks. The response was gratifying, with an apparent remission in the hyperthyroidism and good control ofsymptoms. Despite the short course oftherapy, there was no further evidence ofhyperthyroidism.
Abnormal thyroid function is a recognized feature in some patients with hyperemesis gravidarum. There may be elevation of the serum protein-bound iodine (TBI) and impaired T3 suppression7. Furthermore, transient hyperthyroxinaemia may occur in hyperemesis gravidarum, with raised free thyroxine and free tri-iodothyronine indices, and no TSH response to injection ofTRH'. In our patient, an apparent association was noted between the rise and fall ofthe T4, T3 and HCG levels (Figure 1 ). Although the role of HCG in causing hyperemesis gravidarum in normal and molar pregnancy has been disputed8, HCG or a closely related molecular variant could be responsible for raised serum total T4 levels9 and severe hyperthyroidism'0 in molar pregnancy. We suspect that in this patient, intrinsic TSH-like activity associated with HCG may have been responsible for the transient hyperthyroxinaemia which in turn suppressed the TSH response to TRH stimulation. A recent report of recurrent pregnancy-induced thyrotoxicosis presenting as hyperemesis gravidarum provides further possible evidence for the thyroid-stimulating action of HCG". A similar mechanism has been suggested as an explanation for the transient relapse in early pregnancy of some patients with known Graves' disease but in remission12. Bouillon et al.4 reported that treatment with antithyroid drugs did not modify the clinical course and had no effect on the outcome of the pregnancy. While this may be generally true, we feel that in those patients in whom the abnormality persists or worsens as pregnancy progresses, treatment with antithyroid drugs may rapidly reverse the hyperthyroxinaemia and produce resolution of the hyperemesis. Our experience, in agreement with the report ofJeffcoate and Bain", suggests that a short course only is required and that the antithyroid drugs do not need to be continued once recovery has occurred. The Royal Society of Medicine
